Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

Friday, February 8, 2008 General News J E 4
TUSTIN, Calif., Feb. 7 PeregrinePharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceuticalcompany developing monoclonal antibodies for the treatment of cancer andhepatitis C virus infection, today announced that senior management willpresent at the 10th Annual BIO CEO & Investor Conference on Tuesday, February12, 2008 at 9:30 am EST. The conference will be held at the Waldorf-AstoriaHotel in New York City.

Paul J. Lytle, Peregrine's chief financial officer, will provide a reviewof recent corporate developments.

A live webcast and archived replay of the company's presentation will beavailable at the Investor Relations section of Peregrine's website at

For more information about this conference, please visit:

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with aportfolio of innovative product candidates in clinical trials for thetreatment of cancer and hepatitis C virus (HCV) infection. The company ispursuing three separate clinical programs in cancer and HCV infection with itslead product candidates bavituximab and Cotara(R). Peregrine also has in-housemanufacturing capabilities through its wholly owned subsidiary AvidBioservices, Inc. (, which provides development andbio-manufacturing services for both Peregrine and outside customers.Additional information about Peregrine can be found at GendeLLindheim BioCom Partners Investors Media Barbara Lindheim (800) 987-8256 (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Shengtai Pharmaceutical, Inc. to Present at Roth C...
'The Clinic at Wal-Mart' to Open in Atlanta, Littl...